Skip to main content
. 2015 Jan 15;5(2):530–544.

Figure 3.

Figure 3

Dual kinase inhibitor Lapatinib downregulates ER-α36 expression and sensitizes HER2 expressing cells to tamoxifen. A. Western blot analysis of the expression of phosphorylated EGFR and HER2 in MCF7/HER2-18 treated with indicated concentrations of Lapatinib for 12 hours. B. Western blot analysis of the expression of phosphorylated EGFR and HER2 in BT474 cells treated with indicated concentrations of Lapatinib for 12 hours. C & E. Western blot analysis of the expression of ER-α36 and ER-α66 as well as EGFR and HER2 in parental MCF7, MCF7/HER2-18 and BT474 cells treated with vehicle or indicated concentrations of Lapatinib (LAP) for 12 hours. D & F. Cells were treated with indicated concentrations of tamoxifen (TAM) together with vehicle or 1 μM of Lapatinib (LAP) for seven days and the numbers of survived cells were counted. The columns represent the means of three experiments; bars, SE. * and #, P < 0.05 for cells treated with vehicle vs cells treated with 0.5 and 1 μM of tamoxifen, respectively.